WO2014207490A1 - Agents de contraste de spect/mr(t1), spect/mr(t2) et spect/ct spécifiques d'une tumeur - Google Patents

Agents de contraste de spect/mr(t1), spect/mr(t2) et spect/ct spécifiques d'une tumeur Download PDF

Info

Publication number
WO2014207490A1
WO2014207490A1 PCT/HU2013/000131 HU2013000131W WO2014207490A1 WO 2014207490 A1 WO2014207490 A1 WO 2014207490A1 HU 2013000131 W HU2013000131 W HU 2013000131W WO 2014207490 A1 WO2014207490 A1 WO 2014207490A1
Authority
WO
WIPO (PCT)
Prior art keywords
targeting
biopolymer
nanoparticles
spect
polycation
Prior art date
Application number
PCT/HU2013/000131
Other languages
English (en)
Inventor
Magdolna BODNÁR
János BORBÉLY
Zsuzsanna CSIKÓS
István Hajdu
Original Assignee
Bbs Nanotechnology Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bbs Nanotechnology Ltd. filed Critical Bbs Nanotechnology Ltd.
Publication of WO2014207490A1 publication Critical patent/WO2014207490A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • A61K49/0428—Surface-modified nanoparticles, e.g. immuno-nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles

Definitions

  • the invention relates to cancer receptor-specific bioprobes for single photon emission computed tomography (SPECT) and computed tomography (CT) or magnetic resonance imaging (MRI) for dual modality molecular imaging.
  • the base of the bioprobes is the self-assembled polyelectrolytes, which transport gold nanoparticles as CT contrast agents, or SPION or Gd(III) ions as MR active ligands, and are labeled using complexing agent with technetium-99m as SPECT radiopharmacon.
  • CT contrast agents or SPION or Gd(III) ions as MR active ligands
  • Imaging modalities can be considerable value in molecular imaging, especially for cancers that are difficult to diagnose and treat.
  • This synergistic combination of imaging modalities commonly referred to as image fusion, ensures enhanced visualization of biological targets, thereby providing information on all aspects of structure and function, which is difficult to obtain by a single imaging modality alone.
  • Single photon emission computed tomography allows noninvasive determination of in vivo biodistribution of radiotracers at picomolar concentrations.
  • SPECT single photon emission computed tomography
  • Using specific radiolabeled probes obtaining functional information with high sensitivity about molecular processes is possible.
  • SPECT images however, have limited spatial resolution and lack anatomical details for reference, making the precise localization of lesions difficult.
  • Co-registration of SPECT with anatomical images, from CT or from MR has been commonly used in the clinic to address this problem.
  • nanomedicine approach uses targeted nanoparticles as platforms to design imaging probes for cancer and other human disorders.
  • CT computed tomography
  • nanoparticles of gold are suitable for diagnosis of various different types of cancers.
  • gold with a K-edge at 80.7 keV has higher absorption than iodine (K-edge at 33 keV), thus minimizing bone and tissue interference, which results anatomical references in better contrast with a lower x-ray dose.
  • US Patent 7976825 relates to macromolecular contrast agents for magnetic resonance imaging. Biomolecules and their modified derivatives form stable complexes with paramagnetic ions thus increasing the molecular relaxivity of carriers. The synthesis of biomolecular based nanodevices for targeted delivery of MRI contrast agents is described. Nanoparticles have been constructed by self- assembling of chitosan as polycation and poly-gamma glutamic acids (PGA) as polyanion. The nanoparticles are capable of Gd-ion uptake forming a particle with suitable molecular relaxivity. Folic acid is linked to the nanoparticles to produce bioconjugates that can be used for targeted in vitro delivery to a human cancer cell line.
  • PGA poly-gamma glutamic acids
  • WO06042146 relates to conjugates comprising a nanocamer, a therapeutic agent or imaging agent and a targeting agent.
  • conjugates comprising a nanocarrier, a therapeutic agent or imaging agent, and a targeting agent, wherein the nanocarrier comprises a nanoparticle, an organic polymer, or both.
  • Compositions comprising such conjugates and methods for using the conjugates to deliver therapeutic and/or imaging agents to cells are also disclosed.
  • the conjugate is a compound having the following formula: A-X-Y wherein A represents the chemotherapeutic agent or imaging agent; X represents the nanoparticle, organic polymer or both, wherein the organic polymer has an average molecular weight of at least about 1 ,000 daltons; and Y represents the targeting agent.
  • WO0016811 relates to an MRI contrast agent wherein imaging capability is expressed only within the target abnormal cells, such as tumor, and imaging is not conducted at the site where imaging is not necessary, thereby the detection sensitivity of the abnormal cells such as tumor is improved.
  • an MRI contrast agent which comprises a complex of a polyanionic gadolinium (Gd) type contrast agent and a cationic polymer, or a complex of a polycationic Gd type contrast agent and an anionic polymer, both complexes being capable of forming a polyion complex, and which expresses an MRI capability at a neutral pH in the presence of a polymer electrolyte.
  • Gd gadolinium
  • the present invention is directed to novel, targeting dual-modality SPECT/CT and SPECT/MR tumorspecific contrast agents.
  • the fusion nanoparticulate composition comprises (i) at least two polyelectrolyte biopolymers, (ii) targeting molecules conjugated to a polyelectrolyte biopolymer, (iii) gold nanoparticles coated by the polyelectrolyte biopolymer, (iv) optionally a complexing agent conjugated to the polyelectrolyte biopolymer, and (v) a radionuclide, preferably technetium-99m complexed to the nanoparticles.
  • the fusion nanoparticulate composition comprises (i) at least two polyelectrolyte biopolymers, (ii) targeting molecules conjugated to a polyelectrolyte biopolymer, (iii) a complexing agent conjugated to the polyelectrolyte biopolymer, (iv) superparamagnetic iron oxid nanoparticles coated by the polyelectrolyte biopolymer or Gd ions complexed to the polyelectrolyte biopolymer via complexing agents and (v) a radionuclide, preferably technetium-99m complexed to the nanoparticles.
  • one of the polyelectrolyte biopolymers is polycation, which is preferably chitosan; and the other of the polyelectrolyte biopolymers is polyanion, which is preferably poly- gamma-glutamic acid.
  • the molecular weight of chitosan in the nanoparticles ranges from about 20 kDa to 600 kDa, and the molecular weight of the poly-gamma-glutamic acid in the nanoparticles ranges from about 50 kDa to 1500 kDa. In a preferred embodiment, the degree of deacetylation of chitosan ranges between 40% and 99%.
  • the self-assembled nanoparticles comprise gold nanoparticles, which are coated by a polyelectrolyte biopolymer and this system self-assembles with the other biopolymer to produce stable nanosystem for computed tomography.
  • the gold nanoparticles are synthesized in situ, in the presence of a polyelectrolyte biopolymer or targeting polyelectrolyte biopolymer. In a preferred embodiment the gold nanoparticles are synthesized in presence of poly-gamma-glutamic acid, or folated poly-gamma- glutamic acid.
  • nanoparticulate contrast agent contains superparamagnetic iron oxid nanoparticles (SPION) as T2 MR active ligand, or Gd(III) ions as Tl MR active ligands.
  • SPION superparamagnetic iron oxid nanoparticles
  • Gd(III) ions as Tl MR active ligands.
  • the superparamagnetic iron oxide particles are coated by a polyelectrolyte biopolymer and this system self-assembles with the other biopolymer to produce stable nanosystem for magnetic resonance imaging.
  • the nanoparticles as SPECT/MR fusion contrast agent contain Gd(III) ions as paramagnetic ligands, which are complexed to one of the polyelectrolytes, via the carboxyl groups of polyanion or complexone ligands conjugated to the polycation biopolymer.
  • these self-assembled particles internalize into the targeted tumor cells as a consequence of the presence of targeting ligands.
  • the internalized superparamagnetic contrast agents enhance relaxivity, improve the signal-to-noise and therefore conduct to early tumor diagnosis.
  • the self-assembled nanosystems contain complexing agents, which can facilitate the radioactively labeling due to the complexing process between the complexing agent and the radiopharmacon.
  • Preferred complexing agents include, but are not limited to: diethylenetriaminepentaaceticacid (DTP A), 1 ,4,7, 10-tetracyclododecane-N,- N',N",N'"-tetraaceticacid (DOT A), ethylene-diaminetetraaceticacid (EDTA), 1, 4,7,10-tetraazacyclododecane-N,N',N"- triaceticacid (D03A), l,2-diaminocyclohexane-N,N,N',N'-tetraaceticacid (CHTA), ethyleneglycol- bis(beta-arninoethylether)N,N,N',N',-tetraaceticacid (EGTA), 1,4,8,11-tetraazacyclotradecan
  • nanoparticles as CT or MR contrast agents are radioactively labeled with technetium-99m to produce radiopharmaceutical fusion SPECT/CT or SPECT/MR imaging agent for tumor detection.
  • Targeting moieties are conjugated to one of the self-assembled biopolymers to realize a targeted delivery of imaging agents.
  • the targeting agent is preferably folic acid, LHRH, RGD.
  • the nanoparticles have a mean particle size between about 30 and 500 nm, preferably between about 50 and 400 nm, and most preferably between 70 and 250 nm.
  • the present invention provides fusion imaging agents that are compositions comprising radioactively labeled active nanoparticles.
  • the compositions of the invention target tumor cells, selectively internalize and accumulate in them as a consequence of the presence of targeting ligands, therefore are suitable for early tumor diagnosis.
  • the invention relates to a process for the preparation of a targeting contrast composition according to the invention, comprising the steps of
  • the invention concerns the use of the targeting contrast composition according to the invention as SPECT/MR or SPECT/CT imaging agents in diagniosis, preferably in cancer diagnosis.
  • the present invention provides novel, targeting, self-assembled nanoparticles as dual-modality SPECT/MRI or SPECT/CT tumorspecific contrast agent, method for forming them and methods of using these compositions for targeted delivery.
  • the self-assembled particles are provided as nanocarriers, labeled with targeting moieties, containing complexone ligands conjugated to a polycation biopolymer, MR or CT active ligand complexed to the nanoparticles, and a radionuclide complexed to the nanoparticles.
  • These radiolabeled, dual-modality nanoparticles can specifically internalize and accumulate in the targeted tumor cells to realize the receptor mediated uptake.
  • Radiolabeled, targeted nanoparticulate compositions, methods for making these targeting dual- modality contrast agents, radiolabeling and using such compositions in the field of diagnosis and therapy are also provided.
  • Nanoparticles as contrast agent compositions
  • the present invention is directed to biopolymer-based self-assembled nanocarriers as dual-modality tumorspecific contrast agent for SPECT/MR or SPECT/CT.
  • Biocompatible, biodegradable, polymeric nanoparticles are produced by self-assembly via ion-ion interaction of oppositely charged functional groups of polyelectrolyte biopolymers to form nanocarriers for SPECT and MRI or CT active ligands.
  • the biopolymers are water-soluble, biocompatible, biodegradable polyelectrolyte biopolymers.
  • One of the polyelectrolyte biopolymers is a polycation, a positively charged polymer, which is preferably chitosan or any of its derivatives.
  • the other of the polyelectrolyte biopolymers is a polyanion, a negatively charged biopolymer.
  • the polyanion is preferably selected from a group consisting of polyacrylic acid (PAA), poly-gamma-glutamic acid (PGA), hyaluronic acid (HA), and alginic acid (ALG).
  • the polycation of the nanoparticles ranges in molecular weight from about 20 kDa to 600 kDa, and the polyanion of the nanoparticles ranges in molecular weight from about 50 kDa to 2500 kDa.
  • the degree of deacetylation of chitosan ranges between 40% and 99%.
  • the nanoparticles contain targeting moieties necessary for targeted delivery of nanosystems.
  • the targeting agent is coupled covalently to one of the biopolymers using carbodiimide technique in aqueous media.
  • the water soluble carbodiimide, as coupling agent forms amide bonds between the carboxyl and amino functional groups, therefore the targeting ligand could be covalently bound to one of the polyelectrolyte biopolymers .
  • the preferred targeting agent is selected from folic acid, lutenizing hormone- releasing hormone (LHRH), and an Arg-Gly-Asp (RGD)-containing homodetic cyclic pentapeptide such as cyclo(-RGDf(NMe)V) and the like.
  • the most preferred targeting agent is folic acid, which facilitates the folate mediated uptake of nanoparticles, as tumor specific contrast agents.
  • the nanoparticles of the present invention are preferably targeted to tumor and cancer cells, which overexpress folate receptors on their surface. Due to the binding activity of folic acid ligands, the nanoparticles selectively link to the folate receptors held on the surface of targeted tumor cells, internalize and accumulate in the tumor cells.
  • the folic acid is coupled covalently to the polyanion biopolymer using a carbodiimide technique.
  • the folic acid due to its carboxyl and amino groups can be coupled to the polyanion biopolymer directly or via a PEG-amine spacer.
  • the self-assembled nanoparticles are comprised of a polyanion biopolymer, a polycation biopolymer, a targeting agent covalently attached to one of the biopolymers and at least one complexing agent covalently coupled to the polycation.
  • the complexing agent is coupled covalently to the polycation biopolymer.
  • Water-soluble carbodiimide as coupling agent is used to make stable amide bonds between the carboxyl and arnino functional groups in aqueous media.
  • reactive derivatives of complexing agents e.g. succinimide, thiocyanete
  • the polycation-complexone conjugate can be directly formed in one-step process without any coupling agents.
  • the nanoparticles can make stable complex with the radionuclide metal ions and for SPECT/MRI Tl modality, paramagnetic ions through these complexone ligans.
  • the complexing agents are preferably diethylenetriaminepentaacetic acid (DTPA), 1,4,7,10-tetracyclododecane-N,- N',N",N"'-tetraacetic acid (DOTA), ethylene- diaminetetraacetic acid (EDTA), l,4,7,10-tetraazacyclododecane-N,N',N"-triacetic acid (D03A), 1,2- diaminocyclohexane-N,N,N',N'-tetraacetic acid (CHTA), ethylene glycol-bis(beta-aminoethyl ether)N,N,N',N',-tetraacetic acid (EGTA), 1 ,4,8, 11 -tetraazacyclotradecane-N,N',N",N"'-tetraacetic acid (TETA), l,4,7-triazacyclononane-N,N',N"-tria
  • the targeted, dual-modality self-assembled nanoparticles described herein are radiolabeled with a radionuclide metal ion, which is preferably Tc-99m as SPECT active ligand.
  • the radionuclide metal ions are homogeneously distributed throughout the self-assembled nanoparticle.
  • the radionuclide metal ions can make stable complex with the free complexing agents attached to the polycation biopolymer, therefore they could be performed homogeneously dispersed.
  • Tl or T2 ligands are conjugated to the nanocarriers, and thereafter radiolabelling with radionuclide technetium ( 99 Tc) is carried out.
  • paramagnetic ions are complexed to the nanocarriers.
  • the paramagnetic ions are preferably lanthanide or transition metal ions, more preferably gadolinium-, manganese-, chromium-ions, most preferably gadolinium ions, useful as MRI contrast agent.
  • the paramagnetic ions are homogeneously distributed throughout the self-assembled nanoparticle.
  • paramagnetic ions can make stable complex with the complexone ligands attached to the polycation biopolymer, therefore they could be performed homogeneously dispersed.
  • superparamagnetic ligand preferably superparamagnetic iron oxide nanoparticles are conjugated to a polyelectrolyte biopolymer, and they are preferably homogenously dispersed.
  • the superparamagnetic iron oxide nanoparticles (SPION) are synthesized in situ in the presence of the polyanion, and then the self-assembling with the polycation is performed.
  • Size of dried SPIONs ranges between 1 and 15 nm, preferably 3 and 5 nm.
  • gold nanoparticles are conjugated to the nanocarriers, and thereafter radiolabelling with radionuclide technetium is carried out.
  • the gold nanoparticles are synthesized in situ in the presence of the polyanion, and then the self-assembling with the polycation is performed.
  • the nanoparticles described herein have a hydrodynamic diameter between about 30 and 500 nm, preferably between about 50 and 400 nm, and the most preferred range of the hydrodynamic size of nanoparticles is between 70 and 250 nm.
  • the present invention is directed to novel, radiolabeled, biocompatible, biodegradable, targeting nanoparticles as dual-modality SPECT/MRI or SPECT/CT contrast agents.
  • the nanoparticle compositions described herein are prepared by self-assembly of oppositely charged polyelectrolytes via ion-ion interaction between their functional groups.
  • the targeting ligands are conjugated covalently to one of the polyelectrolyte biopolymers and the complexing agents covalently coupled to the polycation biopolymer.
  • These nanoparticles can contain paramagnetic ligand as MRI Tl, superparamagnetic ligands as MRI T2 agents or gold nanoparticles as CT active ligands.
  • These targeted nanoparticles are radioactively labeled with Tc-99m radionuclide to produce dual-modality fusion contrast agents.
  • the targeting ligand is attached to one of the biopolymers covalently.
  • the targeting agent is preferably folic acid, LHRH, RGD, the most preferably folic acid.
  • Folic acid is coupled covalently to the polyanion biopolymer using the carbodiimide technique. Folic acid due to its carboxyl and amino groups can be coupled to the polyanion biopolymer directly or via a PEG-amine spacer.
  • the polyanion via its reactive carboxyl functional groups can form stable amide bond with the amino functional groups of folic acid or the folic acid-PEG amino spacer using the carbodiimide technique.
  • a folated biopolymer meaning a folated polyanion can be used for the formation of nanoparticles, as targeted dual-modality contrast agent.
  • the polycation derivatives namely polycation-complexone polyelectrolyte derivatives are used for the formation of self-assembled nanoparticles.
  • These derivatives of polycation are produced by coupling complexing agent to it covalently.
  • Water soluble carbodiimide is used as coupling agent to form stable amide linkage between the amino groups of polycation and carboxyl groups of complexing agent.
  • reactive derivatives of complexing agents e.g. succinirnide, thiocyanete
  • the polycation-complexone conjugate can be directly formed in one-step process without any coupling agents.
  • several complexing agent having reactive carboxyl groups are used to make stable complex with metal ions and therefore afford the possibility to use these systems as imaging agent.
  • the concentration of the biopolymer ranges between about 0.05 mg/ml and 5 mg/ml, preferably 0.1 mg/ml and 2 mg/ml, and the most preferably 0.3 mg ml and 1 mg ml.
  • the overall degree of substitution of complexing agent in the polycation-complexone conjugate is generally in the range of about 1-50%, preferably in the range of about 5-30%, and most preferably in the range of about 10-20%.
  • Two types of polycation-complexone conjugate can be used for the formation of nanoparticles: (i) a polycation-complexone conjugate, where the complexing agent specific to the radionuclide is covalently attached to the polycation; and (ii) a polycation-complexone conjugate, when two different complexing agents are covalently coupled to the polycation biopolymer, one of them is specific to the paramagnetic ligand and the other is to the radionuclide.
  • nanoparticulate compositions as targeted, dual-modality SPECT/MRI Tl contrast agents are provided.
  • the Tl MR active agent is a paramagnetic ligand, which is preferably a lanthanide or transition metal ion, more preferably a gadolinium-, a manganese-, a chromium-ion, most preferably a gadolinium ion, useful for MRI.
  • the preferred paramagnetic ions can make stable complex with the targeting, self-assembled nanoparticles due to the complexing agents covalently conjugated to polycation.
  • the gadolinium-chloride solution was used as simple aqueous solution without any pH adjusting.
  • concentration of gadolinium ion ranges between about 0.2 mg/ml and 1 mg/ml, most preferably between 0.4 mg ml and 0.5 mg/ml.
  • the molar ratio of said gadolinium ions and complexone conjugated to the polycation ranges preferably between 1 :10 and 1:1, more preferably 1 : 5 and 1:1, and most preferably 1:1.
  • nanoparticulate compositions as targeted, dual-modality SPECT/MRI T2 contrast agents are provided.
  • the T2 MR active agent is a superparamagnetic ligand, preferably iron- oxide ligand, which is preferably nanoparticulate iron-oxide (SPION), which is complexed to a polyelectrolyte biopolymer, and preferably homogenously dispersed.
  • SPION nanoparticulate iron-oxide
  • the superparamagnetic iron oxide nanoparticles are produced in situ in presence of polyanion or targeted polyanion biopolymers, therefore superparamagnetic iron oxide particles are coated by a polyelectrolyte biopolymer.
  • the SPION synthesis can be performed using several types of Fe(III) and Fe(II) ions, such as pi. FeCl 3 xnH 2 0 (hydrate), Fe 2 (S0 4 ) 3 , Fe(N0 3 ) 3 , Fe(III)-phosphate, FeCl 2 xnH 2 0, FeS0 4 xnH 2 0 (hydrate), Fe(H)-fumarate, or Fe(II)-oxalate.
  • the concentration of polyanion is between 0.01-2.0 mg/ml
  • the ratio of the Fe(III) and Fe(II) ions ranges between 5:1 and 1 :5.
  • the reaction takes place at elevated temperature ranging between 45 and 90 °C under N 2 atmosphere.
  • nanoparticulate compositions as targeted, dual-modality SPECT/CT contrast agents are provided.
  • CT active ligands are gold nanoparticles with size range of 2-15 nm, preferably 5-12 nm.
  • the gold nanoparticles are produced in situ in presence of polyanion or targeted polyanion biopolymer, therefore gold nanoparticles are homogenously dispersed and coated by the polyelectrolyte biopolymer.
  • the concentration of the polyanion is between 0.01-3.0 mg/ml
  • the molar ratio of AuCl 3 and polyanion monomers ranges between 2:1 and 5:1.
  • Synthesis of gold nanoparticles in situ in presence of polyanion may be performed using sodium borohydride as reducing agent and optionally sodium citrate dehydrate as stabilizing agent.
  • the molar ratio of gold chloride, sodium borohydride and optionally sodium citrate dehydrate is 1 : 1 : 1.
  • the Tl MR, T2 MR or CT active ligand bearing nanoparticles are radioactively labeled with SPECT active radionuclide ligand, which is preferably Tc- 99m ion.
  • SPECT active radionuclide ligand which is preferably Tc- 99m ion.
  • the preferred radioactive metal ions can make stable complex with the targeting, self- assembled nanoparticles due to the complexing agents, which are covalently conjugated to polycation.
  • targeted, self-assembled nanoparticles are radiolabeled with Tc-99m to produce dual modality radiodiagnostic imaging agents. The radiolabeling takes place in physiological salt solution.
  • SnC ⁇ (x2H 2 0) as reducing agent is added to nanoparticles, then generator-eluted sodium pertechnetate (" m Tc0 4 " ) is added to the solvent.
  • the incubation temperature for radiolabeling is room temperature, the incubation time for radiolabeling ranges preferably between 2 min and 120 min, more preferably 5 min and 90 min, and the most preferably 30 min and 60 min.
  • the nanocarrier formation of the present invention can be obtained in several steps.
  • a solution of the targeted polyanion and the polycation-complexone are mixed to form stable, self-assembled nanoparticles, and then an aqueous solution of paramagnetic ions is added to these nanoparticles to make stable paramagnetic nanoparticulate contrast agent. Thereafter these paramagnetic nanoparticles are radioactively labeled with Tc-99m SPECT active radionuclide metal ions to produce the fusion contrast agent.
  • SPECT/MR T2 dual-modality contrast agent For production of SPECT/MR T2 dual-modality contrast agent, solution of targeted, SPION-loaded polyanion and polycation-complexone are mixed to form stable, superparamagnetic self-assembled nanoparticles. After that these superparamagnetic nanoparticles are radioactively labeled with Tc-99m SPECT active radionuclide metal ions to produce the fusion contrast agent.
  • SPECT/CT dual-modality contrast agent For the production of a SPECT/CT dual-modality contrast agent, a solution of the targeted, gold nanoparticles-loaded polyanion and the polycation-complexone are mixed to form stable, superparamagnetic self-assembled nanoparticles. Then these CT active nanoparticles are radioactively labeled with Tc-99m SPECT active radionuclide metal ions to produce the fusion contrast agent.
  • the nanoparticle compositions of present invention are prepared by mixing an aqueous solution of the biopolymers at given ratios and order of addition. The polyelectrolytes have statistical distribution inside the nanoparticles to produce globular shape of the nanosystems.
  • the size of nanoparticles can be controlled by several reaction conditions, such as the concentration of biopolymers, the ratio of biopolymers, and the order of addition.
  • the pH of the biopolymer solution is one of the main factors, which influence the nanoparticle formation due to the surface charge of biopolymers.
  • the charge ratio of biopolymers depends on the pH of the environment. In preferred embodiment, for the nanoparticle formation, the pH of the polycation or its derivatives varies between 3.5 and 6.0, and the pH of the aqueous solution of the polyanion or its derivatives ranges between 7.5 and 9.5.
  • Biopolymers with high charge density form stable nanoparticles due to these given pH values.
  • the surface charge of nanoparticles could be influenced by several reaction parameters, such as ratio of biopolymers, ratio of residual functional groups of biopolymers, pH of the biopolymers and the environment, etc.
  • the electrophoretic mobility values of nanoparticles, showing their surface charge could be positive or negative, preferably negative, depending on the reaction conditions described above.
  • the concentration of biopolymers ranges between about 0.005 mg/ml and 2 mg/ml, preferably between 0.2 mg/ml and 1 mg/ml, most preferably 0.3 mg/ml and 0.5 mg/ml.
  • the concentration ratio of biopolymers mixed is about 2:1 to 1:2, most preferably about 1:1.
  • the biopolymers are mixed in a weight ratio of 6:1 to 1:6, most preferably 3:1 to 1:3.
  • the radiolabeled, targeting dual-modality nanoparticle compositions are useful for targeted delivery of radionuclide metal ions MR or CT active ligands coupled or complexed to the nanoparticles.
  • the present invention is directed to methods of using the above-described nanoparticles, as targeted, dual- modality SPECT/MR or SPECT/CT contrast agents.
  • the nanoparticles as nanocarriers deliver the imaging agents to the targeted tumor cells in vitro, therefore can be used as targeted, dual-modality SPECT/MR or SPECT/CT contrast agents.
  • the radiolabeled nanoparticles internalize and accumulate in the targeted tumor cells, which overexpress folate receptors, to facilitate the early tumor diagnosis.
  • the side effect of these contrast agents is minimal, because of the receptor mediated uptake of nanoparticles.
  • the radioactively labeled, targeted dual-modality imaging agents are stable at pH 7.4, they may be injected intravenously. Based on the blood circulation, the nanoparticles could be transported to the area of interest.
  • the osmolality of nanosystems was adjusted using formulating agents.
  • the formulating agent was selected from the group of glucose, physiological salt solution, phosphate buffered saline (PBS), sodium hydrogen carbonate and other infusion base solutions.
  • Radioactively labeled targeted nanoparticles were investigated in vivo using tumor induced animal.
  • Targeted, radiolabeled nanoparticles specifically internalize into the tumor cells overexpressing folate receptors on their surface.
  • the specific localization was examined by SPECT/MR and SPECT/CT methods, and the biodistribution was estimated by quantitative ROI analysis.
  • ⁇ -PGA 60 mg
  • V 100 ml
  • the pH of the polymer solution was adjusted to 6.0.
  • GDI cold water-soluble l-[3- (dimethylamino)propyl]-3-ethylcarbodiimide methiodide
  • the folated poly- ⁇ - glutamic acid ( ⁇ -PGA-FA) was purified by dialysis.
  • ⁇ -PGA 300 mg
  • V 300 ml
  • aqueous solution at a concentration of 1 mg/ml.
  • the pH of the polymer solution was adjusted to 6.0.
  • the reaction mixture was sonicated for 5 min.
  • EDC cold water-soluble l-[3-(d1methylamino)propyl]-3-ethylcarbodiirnide hydrochloride
  • the reaction mixture was stirred for 24 h.
  • the folated poly-y-glutamic acid ( ⁇ -PGA-PEG-FA) was purified using mPES MicroKros Filter Module (10 kD).
  • the pH of the reaction mixture was raised to 8.5 and after that it was reduced to 6.0.
  • Radiochemical purity was examined by means of thin-layer chromatography, using silica gel as the coating substance on a glass-fibre sheet (ITLC-SG). Plates were developed in methyl ethyl ketone. Free, unbound 99ra Tc-pertechnetate migrated with the solvent to the front line, while the labelled nanoparticle compound was located at the origin (bottom).
  • the Raytest MiniGita device Mini Gamma Isotope Thin Layer Analyzer
  • the labelling efficiency was examined 1 h, 6 h and 24 h after labeling. Radiochemical samples were stored at room temperature in a dark place. The radiolabeled products showed high degree and durable labelling efficiency above 99% (Fig 5).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des biosondes spécifiques d'un récepteur du cancer pour une tomographie d'émission monophotonique (SPECT) et tomographie assistée par ordinateur (CT) ou imagerie par résonance magnétique (IRM) pour une imagerie moléculaire à double modalité. La base de biosondes est constituée de polyélectrolytes auto-assemblés, qui transportent des nanoparticules d'or comme agents de contraste de CT, ou des ions SPION ou Gd(III) en tant que ligands actifs de MR, et sont marqués à l'aide d'un agent complexant par du technetium-99m en tant que radiopharmacon de SPECT. En outre, ces agents de contraste de SPECT/CT et SPECT/MR à double modalité sont marqués par des fractions de ciblage pour réaliser la spécificité de tumeur.
PCT/HU2013/000131 2013-06-28 2013-12-19 Agents de contraste de spect/mr(t1), spect/mr(t2) et spect/ct spécifiques d'une tumeur WO2014207490A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361840483P 2013-06-28 2013-06-28
US61/840,483 2013-06-28

Publications (1)

Publication Number Publication Date
WO2014207490A1 true WO2014207490A1 (fr) 2014-12-31

Family

ID=52115793

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU2013/000131 WO2014207490A1 (fr) 2013-06-28 2013-12-19 Agents de contraste de spect/mr(t1), spect/mr(t2) et spect/ct spécifiques d'une tumeur

Country Status (2)

Country Link
US (1) US20150004096A1 (fr)
WO (1) WO2014207490A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105233307A (zh) * 2015-10-21 2016-01-13 上海大学 小尺寸稀土纳米金生物探针的制备方法
WO2018107205A1 (fr) * 2016-12-16 2018-06-21 The Australian National University Matériau radiomarqué pour administration ciblée
CN108635595A (zh) * 2018-07-04 2018-10-12 东华大学 基于光响应聚合的超小氧化铁纳米探针及其制备和应用
CN109912694A (zh) * 2017-12-12 2019-06-21 首都医科大学 Rgdf修饰的七环醛, 其制备，抗栓活性和应用
CN111603572A (zh) * 2020-06-02 2020-09-01 珠海市人民医院 纳米造影剂及其制备方法、应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3075649A1 (fr) * 2017-12-22 2019-06-28 Mexbrain Dispositif pour le maintien de l'homeostasie metallique, et ses utilisations
CN108578427B (zh) * 2018-03-01 2020-11-17 苏州大学 叶酸修饰的金纳米颗粒及其制备方法与在制备放射增敏治疗药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7976825B2 (en) * 2007-12-06 2011-07-12 Janos Borbely Cancer cell diagnosis by targeting delivery of nanodevices

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7976825B2 (en) * 2007-12-06 2011-07-12 Janos Borbely Cancer cell diagnosis by targeting delivery of nanodevices

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HAJDU ISTVAN ET AL.: "Cancer cell targeting and imaging with biopolymer-based nanodevices.", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 441, 2013, pages 234 - 241 *
POLYAK ANDRAS ET AL.: "99mTc-labelled nanosystem as tumour imaging agent for SPECT and SPECT/CT modalities.", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 449, April 2013 (2013-04-01), pages 10 - 17 *
TERMSARASAB UBONVAN ET AL.: "Self-assembled magnetic resonance imaging nanoprobes based on arachidyl chitosan for cancer diagnosis.", COLLOIDS AND SURFACES B: BIOINTERFACES, vol. 109, March 2013 (2013-03-01), pages 280 - 286 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105233307A (zh) * 2015-10-21 2016-01-13 上海大学 小尺寸稀土纳米金生物探针的制备方法
CN105233307B (zh) * 2015-10-21 2018-12-07 上海大学 小尺寸稀土纳米金生物探针的制备方法
WO2018107205A1 (fr) * 2016-12-16 2018-06-21 The Australian National University Matériau radiomarqué pour administration ciblée
AU2017376822B2 (en) * 2016-12-16 2023-08-03 The Australian National University Radiolabelled material for targeted administration
US11896683B2 (en) 2016-12-16 2024-02-13 The Australian National University Radiolabelled material for targeted administration
CN109912694A (zh) * 2017-12-12 2019-06-21 首都医科大学 Rgdf修饰的七环醛, 其制备，抗栓活性和应用
CN108635595A (zh) * 2018-07-04 2018-10-12 东华大学 基于光响应聚合的超小氧化铁纳米探针及其制备和应用
CN108635595B (zh) * 2018-07-04 2019-11-08 东华大学 基于光响应聚合的超小氧化铁纳米探针及其制备和应用
CN111603572A (zh) * 2020-06-02 2020-09-01 珠海市人民医院 纳米造影剂及其制备方法、应用
CN111603572B (zh) * 2020-06-02 2022-03-29 珠海市人民医院 纳米造影剂及其制备方法

Also Published As

Publication number Publication date
US20150004096A1 (en) 2015-01-01

Similar Documents

Publication Publication Date Title
Li et al. 99mTc-labeled multifunctional low-generation dendrimer-entrapped gold nanoparticles for targeted SPECT/CT dual-mode imaging of tumors
US20150004096A1 (en) Tumorspecific SPECT/MR(T1), SPECT/MR(T2) and SPECT/CT contrast agents
Farzin et al. An overview of nanoscale radionuclides and radiolabeled nanomaterials commonly used for nuclear molecular imaging and therapeutic functions
Yang et al. Affibody modified and radiolabeled gold–iron oxide hetero-nanostructures for tumor PET, optical and MR imaging
US20150004103A1 (en) Tumorspecific PET/MR(T1), PET/MR(T2) and PET/CT contrast agent
Hamoudeh et al. Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer
Hirsjärvi et al. Effect of particle size on the biodistribution of lipid nanocapsules: comparison between nuclear and fluorescence imaging and counting
US20040258614A1 (en) Microparticles for microarterial imaging and radiotherapy
JPH09509400A (ja) 改良された部位選択的局在化、取り込み機序、感度および動力学的空間的特徴を与える、酸性サッカライドおよびグリコサミノグリカンとの放射性金属イオンキレートよりなるインビボ薬剤
Polyák et al. 99mTc-labelled nanosystem as tumour imaging agent for SPECT and SPECT/CT modalities
HUT77993A (hu) Vastartalmú, kettős bevonatú nanorészecskék, ezek előállítása és alkalmazása a diagnosztikában, és a gyógykezelésben
WO2017126939A1 (fr) Nanoparticule biocompatible et son utilisation
Gholipour et al. Development of Ga-68 labeled, biotinylated thiosemicarbazone dextran-coated iron oxide nanoparticles as multimodal PET/MRI probe
Zhao et al. Polyethylenimine-based theranostic nanoplatform for glioma-targeting single-photon emission computed tomography imaging and anticancer drug delivery
Orocio-Rodríguez et al. Two novel nanosized radiolabeled analogues of somatostatin for neuroendocrine tumor imaging
Li et al. Design of 99m Tc-labeled low generation dendrimer-entrapped gold nanoparticles for targeted single photon emission computed tomography/computed tomography imaging of gliomas
He et al. Immune activity and biodistribution of polypeptide K237 and folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles radiolabeled with 99mTc
Wang et al. One pot synthesis of zwitteronic 99mTc doped ultrasmall iron oxide nanoparticles for SPECT/T1-weighted MR dual-modality tumor imaging
Liu et al. Synthesis, biodistribution, and imaging of PEGylated-acetylated polyamidoamine dendrimers
Varani et al. Radiolabelled nanoparticles for cancer diagnosis
Cao et al. Chelator-free conjugation of 99mTc and Gd3+ to PEGylated nanographene oxide for dual-modality SPECT/MR imaging of lymph nodes
Liu et al. Radioiodinated tyrosine based carbon dots with efficient renal clearance for single photon emission computed tomography of tumor
Han et al. Spatiotemporal tracking of gold nanorods after intranasal administration for brain targeting
Ahmadi et al. Pharmacokinetics and biodistribution studies of [99mTc]-Labeled ZIF-8 nanoparticles to pave the way for image-guided drug delivery and theranostics
Ekinci et al. Radiolabeled methotrexate loaded chitosan nanoparticles as imaging probe for breast cancer: Biodistribution in tumor-bearing mice

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13887703

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13887703

Country of ref document: EP

Kind code of ref document: A1